R&D Tax Credits for Providence, Rhode Island Businesses

Providence, Rhode Island, is a major hub for industries such as healthcare, education, finance, technology, and manufacturing. Top companies in the city include Lifespan, a leading healthcare provider; Brown University, a major educational institution; Citizens Financial Group, a significant finance employer; CVS Health, a key player in the technology sector; and Textron, a prominent manufacturing company. The Research and Development (R&D) Tax Credit can help these industries save on taxes by encouraging innovation and technological advancements.

find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 270 Bellevue Avenue, Newport, Rhode Island is less than 40 miles away from Providence and provides R&D tax credit consulting and advisory services to Providence and the surrounding areas such as: Warwick, Cranston, Pawtucket, Woonsocket and Fall River.

If you have any questions or need further assistance, please call or email our local Rhode Island Partner on (401) 406-8880.
Feel free to book a quick teleconference with one of our Rhode Island R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Providence, Rhode Island Patent of the Year – 2024/2025

EpiVax Inc. has been awarded the 2024/2025 Patent of the Year for its pioneering work in immune modulation. Their invention, detailed in U.S. Patent No. 11911414, titled ‘Regulatory T cell epitopes’, introduces a novel method to induce regulatory T-cells using specific peptide sequences, aiming to suppress unwanted immune responses.

In a significant advancement for immunotherapy, EpiVax Inc. has developed a method to harness the body’s own regulatory T-cells to modulate immune responses. This approach utilizes specific peptide sequences, known as T-cell epitopes, to activate these regulatory cells, potentially offering new treatments for autoimmune diseases and allergies.

The patented method involves administering a composition containing isolated T-cell epitope polypeptides, with at least one matching a defined amino acid sequence. This composition can suppress various immune responses, including those from effector T-cells, helper T-cells, and B-cells, by promoting the activity of natural or adaptive regulatory T-cells.

By targeting the immune system’s regulatory mechanisms, this innovation offers a more precise approach to controlling immune responses. It holds promise for conditions where the immune system is overactive or misdirected, providing a potential alternative to broad-spectrum immunosuppressive therapies.

EpiVax Inc.’s development represents a step forward in personalized medicine, offering the potential for treatments that are both effective and tailored to individual immune profiles.